Showing 5671-5680 of 6035 results for "".
- Zeiss Launches First Dual-Speed Swept-Source OCT/OCTA at ARVOhttps://modernod.com/news/zeiss-launches-first-dual-speed-swept-source-oct-octa-at-arvo/2476503/Zeiss launched the PLEX Elite 2.0, the first dual-speed swept-source OCT/OCTA that will scan at 200kHz, in addition to 100kHz, providing doctors a more detailed view into the retina. Varying speeds can be applied to different disease states in the eye and expand re
- Presbia Abandons Flexivue Microlens, Lays Off All But 3https://modernod.com/news/presbia-abandons-flexivue-microlens-lays-off-all-but-3/2476501/Presbia said it spiked its Flexivue microlens development program in the face of FDA headwinds, laying off all but three of its employees as it seeks investors to bail it out, according to a Mass Device report. Earlier this month, the Irvine, Calif.-based company
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula
- Optos Wins 2019 Queen’s Award for Enterprise Innovationhttps://modernod.com/news/optos-wins-2019-queens-award-for-enterprise-innovation/2476489/UK-based Optos has been recognized for its innovation with a 2019 Queen’s Award for Enterprise. Optos, which has sold more than 16,000 of its ultra-widefield imaging devices to eyecare professionals across the world, won the coveted accolade for the design of its
- Ivantis Announces Publication of Comparative MIGS Clinical Trial Resultshttps://modernod.com/news/ivantis-announces-publication-of-comparative-migs-clinical-trial-results/2476486/Ivantis, developer of the Hydrus Microstent, announced that the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS) were accepted into the journal Ophthalmology, according to a company news release. COMPARE is the first prospective, multicenter, ra
- GenSight Biologics Reports Positive Follow-Up Results of Phase 3 Trial in LHONhttps://modernod.com/news/gensight-biologics-reports-positive-follow-up-results-of-phase-3-trial-in-lhon/2476475/GenSight Biologics announced results from the second scheduled readout, at week 72, of the RESCUE phase 3 clinical trial evaluating the safety and efficacy of a single intravitreal injection of GS010 (rAAV2/2-ND4) in 39 subjects whose visual loss due to 11778-ND4 Leber Hereditar
- Ophthotech Changes Name to Iveric bio as it Transitions to Gene Therapy Companyhttps://modernod.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/Ophthotech announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the company
- Visioneering Technologies Creates Educational Series for Eye Care Practitionershttps://modernod.com/news/visioneering-technologies-creates-educational-series-for-eye-care-practitioners/2476471/Visioneering Technologies, maker of the NaturalVue Multifocal 1 Day contact lenses, announced the creation of a new educational series for eye care practitioners featuring some of the world’s leading researchers and clinicians, according to a company news release. The first installment of
- Novartis Announces FDA BLA Acceptance of Brolucizumab for Wet AMDhttps://modernod.com/news/novartis-announces-fda-filing-acceptance-and-priority-review-of-brolucizumab-for-wet-amd/2476468/Novartis announced that the FDA has accepted the company’s biologics license application (BLA) for brolucizumab (RTH258) for the treatment of wet age-related macular degeneration (AMD). Novartis used a priority review voucher to expedite FDA review and anticipates launching brolucizumab, if
- Alimera Sciences Appoints Samer Kaba, MD, as Chief Medical Officerhttps://modernod.com/news/alimera-sciences-appoints-samer-kaba-md-as-chief-medical-officer/2476464/Alimera Sciences announced an expansion of its leadership team with the appointment of Samer Kaba, MD, as Chief Medical Officer, effective April 4, 2019. “I am very pleased that Samer will be joining us in this new position as he will bring both a physician’s perspect